Article

BRAF V600E-mutant intrahepatic cholangiocarcinoma treated successfully with encorafenib, binimetinib, and cetuximab

2025-05-08

Abstract excerpt

<title>Abstract</title> <p><italic>BRAF</italic> mutations, particularly <italic>BRAF</italic> V600E, are rare but significant molecular alterations in intrahepatic cholangiocarcinoma (IHCC), often associated with aggressive disease and poor prognosis. Although targeted therapies have demonstrated efficacy in <italic>BRAF</italic>-mutant colorectal cancer, their role in IHCC remains unclear. Herein, we report the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f1fa0a9d-7bba-5ac4-9414-1fdc42456323
DOI: 10.21203/rs.3.rs-6384501/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

BRAF V600E-mutant intrahepatic cholangiocarcinoma treated successfully with encorafenib, binimetinib, and cetuximabDOI 10.21203/rs.3.rs-6384501/v1Read

Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review.Semantic proximity Read

[Treatment with dabrafenib and trametinib in an intrahepatic cholangiocarcinoma harboring a BRAF V600E mutation].Semantic proximity Read

Untitled literature recordSemantic proximity Read

Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experienceSemantic proximity Read

Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.Semantic proximity Read

The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.Semantic proximity Read

Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.Semantic proximity Read

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.Semantic proximity Read

Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.Semantic proximity Read

BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.Semantic proximity Read

Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.Semantic proximity Read

Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.Semantic proximity Read